Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial. [electronic resource]
Producer: 20171011Description: 3986-3994 p. digitalISSN:- 1097-0142
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Squamous Cell -- drug therapy
- China
- Cisplatin -- administration & dosage
- Disease-Free Survival
- Esophageal Neoplasms -- metabolism
- Female
- Fluorouracil -- administration & dosage
- Humans
- Lymphotoxin-alpha -- adverse effects
- Male
- Middle Aged
- Receptors, Tumor Necrosis Factor, Type II -- blood
- Recombinant Proteins -- adverse effects
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.